Author | Jason M. Broderick


Darolutamide survival benefit in prostate cancer highlighted in NEJM

September 11, 2020

Updated results were also reported on other key end points, including time to pain progression, first symptomatic skeletal event, and initiation of chemotherapy.

Nivolumab/ipilimumab dual immune-checkpoint blockade active in mCRPC

September 10, 2020

Combination approach could overcome mechanisms that previously led to poor outcomes with single-agent checkpoint inhibition.

PSA screening in prostate cancer: The controversy continues

September 09, 2020

A new analysis supports return to widespread screening.

HIFU allows 91% of patients to avoid radical prostate cancer treatment for 2 years

September 08, 2020

The results suggest the minimally-invasive procedure is an acceptable alternative to immediate surgery or radiation.